Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

A new study evaluates the efficacy of vaccine- and infection-induced antibodies against SARS-CoV-2 variants.

19 Jul 2021

Antibody levels remain high nine months after SARS-CoV-2 infection, study shows

Testing of an entire Italian town shows antibody levels remain high nine months after SARS-CoV-2 infection, whether symptomatic or asymptomatic.

19 Jul 2021

Researchers find a potentially game-changing blood clot treatment

A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University's Jeffrey Weitz.

19 Jul 2021

New research may offer clues to why MS patients develop progressive disability

Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not.

19 Jul 2021

Study: Second dose of COVID-19 vaccine induces a powerful boost to the immune system

The second dose of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study led by investigators at the Stanford University School of Medicine.

19 Jul 2021

Researchers discover major metabolite involved in regulating intestinal bacteria

Researchers at the RIKEN Center for Integrative Medical Sciences (IMS) have discovered that acetate, a major metabolite produced by some intestinal bacteria, is involved in regulating other intestinal bacteria.

19 Jul 2021

Study suggests children develop short-term humoral immunity following SARS-CoV-2 infection

A single-center, cross-sectional epidemiological survey conducted in Israel has recently pointed out that antibodies induced by natural SARS-CoV-2 infection in children start declining just after 4 months of acute infection. However, their seropositivity rates are not impacted by school reopening. The study has recently been published in the journal Acta Paediatrica.

19 Jul 2021

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

A team of scientists from the United States has recently compared the epitope-specific T cell response after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination in both naïve and previously infected individuals.

19 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Oxygen therapy may improve hypoxia-induced B cell abnormalities in COVID-19

Researchers in the United States have demonstrated early and persistent B cell abnormalities in patients with moderate or severe coronavirus disease 2019 (COVID-19) that may be largely driven by hypoxia.

18 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Infection fatality rate of COVID-19 in community-based elderly lower than earlier estimates

A new study discusses the results obtained from various seroprevalence studies conducted in 2020.

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

Researchers isolate human monoclonal antibodies that may neutralize several norovirus variants

Researchers at Vanderbilt University Medical Center and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.

16 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Mixing COVID vaccines generates a comparable immune response

The validity and safety of mixing first and second doses of different types are explored in a paper recently uploaded to the preprint server medRxiv* by Rose et al. (July 13th, 2021), finding that robust antibody response is induced, comparable to, and perhaps even exceed that generated by homologous dosing.

16 Jul 2021

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Researchers in the United States have designed a modular protein subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited a strong immune response in macaques and prevented the animals from developing coronavirus disease 2019 (COVID-19).

15 Jul 2021

A rapid, highly accurate test to detect antibodies against SARS-CoV-2 in human serum

Scientists have developed a rapid, highly accurate test to detect antibodies against the spike protein of SARS-CoV-2 in human serum, opening a new avenue for understanding the full extent of the pandemic and evaluating the effectiveness of vaccines.

15 Jul 2021

Antibody News and Research

Further Reading

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Antibody levels remain high nine months after SARS-CoV-2 infection, study shows

Researchers find a potentially game-changing blood clot treatment

New research may offer clues to why MS patients develop progressive disability

Study: Second dose of COVID-19 vaccine induces a powerful boost to the immune system

Researchers discover major metabolite involved in regulating intestinal bacteria

Study suggests children develop short-term humoral immunity following SARS-CoV-2 infection

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

Oxygen therapy may improve hypoxia-induced B cell abnormalities in COVID-19

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

How do immunocompromised patients respond to COVID-19 vaccines?

Infection fatality rate of COVID-19 in community-based elderly lower than earlier estimates

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

Researchers isolate human monoclonal antibodies that may neutralize several norovirus variants

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

Mixing COVID vaccines generates a comparable immune response

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

A rapid, highly accurate test to detect antibodies against SARS-CoV-2 in human serum

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo